Nexus: A versatile console for advanced low-field MRI.

Purpose: To develop a low-cost, high-performance, versatile, open-source console for low-field MRI applications that can integrate a multitude of different auxiliary sensors.

Methods: A new MR console was realized with four transmission and eight reception channels. The interface cards for signal transmission and reception are installed in PCI Express slots, allowing console integration in a commercial PC rack.

Scp776, A Novel IGF-1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo-Controlled Phase 1 Studies in Healthy Adults.

Apoptosis is a major driver of cell loss and infarct expansion in ischemic injuries such as acute ischemic stroke (AIS) and acute myocardial infarction (AMI). Insulin-like growth factor-1 (IGF-1) can mitigate cell death and potentiate recovery following acute ischemic injury, but short half-life and nonspecificity limit its therapeutic potential. Scp776 is an IGF-1 fusion protein designed to target damaged tissue and promote apoptosis escape and is in clinical development as an acute therapy for AIS and AMI.

Denoising low-field MR images with a deep learning algorithm based on simulated data from easily accessible open-source software.

In this study, we introduce a denoising method aimed at improving the contrast ratio in low-field MRI (LFMRI) using an advanced 3D deep convolutional residual network model. Our approach employs synthetic brain imaging datasets that closely mimic the contrast and noise characteristics of LFMRI scans, addressing the limitation of available in-vivo LFMRI datasets for training deep learning models. In the simulation data, the Relative Contrast Ratio (RCR) increased, and similar improvements were observed in the in-vivo data across different imaging conditions.

Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults.

Islatravir is a deoxynucleoside analog being developed for the treatment of HIV-1 infection. Clinical studies are being conducted to evaluate islatravir, administered in combination with other antiretroviral therapies, at doses of 0.25 mg once daily and 2 mg once weekly.

Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.

Gefapixant (MK-7264, RO4926219, AF-219) is a first-in-class P2X3 antagonists being developed to treat refractory or unexplained chronic cough. The initial single- and multiple-dose safety, tolerability, and pharmacokinetics of gefapixant at doses ranging from 7.5 to 1800 mg were assessed in four clinical trials.